6/22/2023 0 Comments Pcr complete responseMulti-agent chemotherapy was associated with higher likelihood of pCR, but this effect was modest compared to other factors. In all patients, pCR was associated with improved survival ( pā<ā0.01). Patients receiving multi-agent chemotherapy were younger, had fewer comorbidities, and had higher cT stage and grade. pCR was achieved in 46% of cT2 patients and 43% of cT1, and in 46% of patients treated with multi-agent versus 38% single agent. Multi-agent NAC was given to 90% of women while single-agent NAC was given to 10% of women. In total, 6994 patients were included, 32% cT1 and 68% cT2. Factors associated with pathologic complete response (pCR) and overall survival were examined. We conducted a cohort study of adult women with T1-2/cN0 HER2+ breast cancer diagnosed 2013ā2016 in the National Cancer Database treated with neoadjuvant chemotherapy (NAC) and HER2-targeted therapy. The role of de-escalated therapy in the neoadjuvant setting, however, remains uncertain. 11.7% (95% CI 3.6-25.1) and 9.1% (95% CI 3.3-18.5) for patients with Further research should consider an analysis of a larger population of STS patients, delving into the correlation between hyalinization/fibrosis to oncologic outcomes, assessing imaging and pCR in relation to disease outcomes, and clarifying specific histologic types that may benefit from treatment intensification and personalized therapy to help strengthen the findings of this study.Women with small HER2+ breast cancers may have excellent prognosis with adjuvant single-agent chemotherapy and HER2-targeted therapy. The 5-year OS rate is 100% for patients with pCR versus 76.5% (95% CI 62.3-90.8) and 56.4% (95% CI 43.3-69.5) for patients with Five-year LF rate was 0% in patients with pCR vs. NRG-RTOG 06 combined included 123 patients that were evaluable for pCR as 14 out of 51 (27.5%) on 9514 and 14 out of 72 (19.4%) on 0630 had pCR. These results have also established that the reduced target volumes that were used during this study are appropriate for preoperative IGRT. The results, published in this manuscript, indicate the estimated 5-year overall survival (OS) is 62.1% (95% confidence interval 51.2-73.0) and the estimated 5-year local failure (LF) rate is 12.7% (95% CI 6.5-21.1). The long-term results of NRG-RTOG 0630 analyzed 79 patients with STS at a median follow-up of 6 years for surviving patients. In this analysis, we strived to connect the treatment-induced pCR of STS patients receiving these relatively uniformed treatment regimens to their recently reported long-term outcomes," stated Dian Wang, MD, Ph.D., FASTRO, of the Rush University Medical Center and the Lead Author of the NRG-RTOG 0630/9514 manuscript. "Previously, all information that researchers had regarding the prognostic impact of pCR to therapy for STS patients was limited, unclear, and often offered conflicting results. The primary objective of the combined ancillary analysis was to correlate percentage tumor viability after surgery with survival and disease outcomes for this patient population on these two studies. NRG-RTOG 06 both evaluated STS patients who were receiving either preoperative image-guided radiotherapy (IGRT 0630) or neoadjuvant chemoradiotherapy (9514). These results were recently published in the JAMA Oncology. This data suggests that pCR can be used as a prognostic factor for clinical outcomes in future STS research.
0 Comments
Leave a Reply. |